Key Takeaways
Extended Takeaways
- This phase 3 trial enrolled a moderately to severely ill inadequate-response population, with baseline MADRS total scores of 32.0–33.0, CGI-S scores of 4.6–4.7, and a current major depressive episode lasting 6 to 7 months, so the negative result applies to a clearly symptomatic adjunctive-treatment population rather than mildly ill patients.
- The absolute separation from placebo on the primary endpoint was small at week 6: MADRS LS mean change was −13.8 with cariprazine 1.5 mg/d, −14.8 with cariprazine 3 mg/d, and −13.4 with placebo, which is consistent with a strong placebo response limiting signal detection.
- If cariprazine is used adjunctively in major depressive disorder, early symptom shifts may be more informative than waiting for a large week-6 advantage in every patient, because unadjusted MADRS differences favored cariprazine 3 mg/d at weeks 1, 2, and 4 and cariprazine 1.5 mg/d at week 2.
- Tolerability was driven mainly by akathisia/restlessness rather than broader extrapyramidal burden: scale-derived treatment-emergent akathisia occurred in 13 (5.2%) placebo-, 27 (10.8%) cariprazine 1.5 mg/d–, and 30 (12.0%) cariprazine 3 mg/d–treated patients, while scale-derived parkinsonism was 3 (1.2%), 4 (1.6%), and 4 (1.6%), respectively.
- Discontinuation risk from adverse effects was low overall, but akathisia was the main reason to stop treatment, leading to discontinuation in 2 (0.8%) patients on cariprazine 1.5 mg/d, 6 (2.4%) on cariprazine 3 mg/d, and 2 (0.8%) on placebo.
- Metabolic and cardiac changes were limited over 6 weeks: mean weight change was < 1 kg in all groups, weight increase ≥ 7% occurred in 0.8% with placebo, 0.4% with cariprazine 1.5 mg/d, and 2.0% with cariprazine 3 mg/d, and no patient had QTcF increase > 60 msec from baseline or QTcF interval > 500 msec.
